| Date | Title | Description |
| 04.02.2026 | Two publications and an FDA fast track designation for Swiss biotechs |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company focused on developing advanced therapies for inflammatory diseases, announced that its lead asset, sonelokimab, has been granted Fast Track designation by the U.S. Foo... |
| 07.11.2025 | Development milestones and financing for biotech companies |
Timeline, a longevity biotech company behind Mitopure® (Urolithin A) — a postbiotic that stimulates mitophagy, the body’s cellular recycling process critical for mitochondrial and metabolic health — has published a new clinical study on im... |
| 23.02.2024 | Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline | - |
| 19.02.2024 | Alys Pharmaceuticals: Revolutionizing Dermatology Treatment | Alys Pharmaceuticals, a game-changer in immuno-dermatology, emerges with a $100 million boost from Medicxi. Combining the strengths of six Medicxi biotech firms, Alys sets out to reshape the landscape of dermatological treatments. With a pi... |
| 16.02.2024 | The Week’s 10 Biggest Funding Rounds: Lambda Leads Massive Week For Megadeals | 10 Shares Email Facebook Twitter LinkedIn
Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board.
This is a ... |
| 14.02.2024 | Medicxi invests $100 million in newly launched Alys Pharmaceuticals |
Founded by consolidating six existing Medicxi biotech firms, Alys Pharmaceuticals aims to transform the treatment paradigm for several dermatology conditions. The company combines the assets and platforms of Aldena Therapeutics, Granular T... |
| 12.02.2024 | Alys Pharmaceuticals Raises $100M in Financing | Alys Pharmaceuticals, Inc., a Boston, MA- and Geneva, Switzerland-based immuno-dermatology focused company, launched with a $100m funding from Medicxi.
Co-founded by Medicxi and several world leading dermatology and scientific experts, incl... |
| 12.02.2024 | Alys Pharmaceuticals Launches with $100M Financing |
BOSTON, MA, Alys Pharmaceuticals, an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
>> Click here for more funding data... |
| - | Alys Pharmaceuticals | “Alys Pharmaceuticals – An Innovation Leader in Immuno-Dermatology” |
